Our immune system has vital roles in supporting and protecting against cancer development. In a highly complex network of interacting cells, immune cells both promote cancer cell growth and survival and selectively kill malignant cells. It is this killing ability that cancer cells must escape from in order to survive and flourish.
Research into the basic science of cancer immunology has enabled us to harness the power of the immune system to treat cancer. We are now entering a golden age of immunotherapy where new, sophisticated and innovative treatments are providing unprecedented cures for patients with advanced cancers.
Chimeric antigen receptor (CAR) T cells are genetically engineered immune cells that can seek out and destroy cancer cells. So far, results have been very promising, but the use of CAR-T cells is associated with frequent, serious short-term toxicities.
This handy resource explains what CAR-T cells are and how they were developed, discusses the results of clinical trials and the management of toxicities, and outlines future improvements and applications. It is ideal reading for any healthcare professional wanting to know more about this exciting therapeutic field.
This course was commissioned by Leukaemia Care and was written by Richard J Buka MBChB(Hons) BMedSc(Hons) MRCP on behalf of Karger.
For each chapter, we have produced a workbook that you can download and keep. The pass mark for this course is 70%.
Completion of this course will take approximately 4 hours (1 hour per chapter) and the certificates provided can be used towards your revalidation.
For any queries about the content of the CAR-T course, including references, please email firstname.lastname@example.org